公开(公告)号：US20140377262A1

公开(公告)日：2014-12-25

申请号：US14375675

申请日：2013-01-31

Applicant: OSAKA UNIVERSITY ,  THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD. ,  DEPARTMENT OF MEDICAL SCIENCES

Inventor： Mayo Yasugi ,  Motoki Kuhara ,  Jotika Boon-Long ,  Kazuhito Fujiyama ,  Ritsuko Koketsu ,  Kazuyoshi Ikuta

IPC: C07K16/10 ,  G01N33/569

CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56983 ,  G01N2333/11

Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.

Abstract translation: 提供了用于治疗人类B型流感病毒的材料和方法。 提供了抗人流感病毒单克隆抗体及其对人类B型流感病毒具有中和活性的抗原结合片段。 还提供了产生抗人B型流感病毒单克隆抗体的方法。 抗体及其抗原结合片段对于广泛的乙型流感病毒株是有效的。 提供了抑制或治疗人流感B感染的方法。 抗乙型流感病毒治疗剂也可用于制造有效抗B型流感病毒的药物，以检测人类受试者中的人类流感B，用于药物组合物，并用于至少一种预防，治疗 ，以及人类受试者中人类乙型流感的检测。

公开(公告)号：US20140065180A1

公开(公告)日：2014-03-06

申请号：US14070948

申请日：2013-11-04

Applicant: The Research Foundation for Microbial Diseases of Osaka University ,  Japan as Represented by the Director-General of National Inst. of Infectious Diseases

Inventor： Asato KOJIMA ,  Hidehiro TAKAHASHI ,  Toyokazu ISHIKAWA

IPC: A61K39/12

CPC classification number: A61K39/12 ,  A61K31/711 ,  A61K2039/5258 ,  C07K14/005 ,  C12N2770/24122 ,  C12N2770/24134 ,  Y02A50/394

Abstract: The invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the VLP secretion expression vector as an active ingredient.

Abstract translation: 本发明提供通过改变源自西尼罗病毒（WNV）的信号序列获得的高度分泌或产生信号肽的病毒样颗粒（VLP），信号肽，含有编码prM蛋白和E的核酸的WNV VLP分泌表达载体 蛋白质，含有载体的WNP VLP高度分泌或产生动物细胞系，含有通过细胞系获得的WNV VLP作为活性成分的WNV疫苗和含有VLP分泌表达载体作为活性成分的WNV DNA疫苗。

公开(公告)号：US11633469B2

公开(公告)日：2023-04-25

申请号：US16316186

申请日：2017-07-11

Applicant: The Research Foundation for Microbial Diseases of Osaka University

Inventor： Takao Fujimoto ,  Junji Fujita

IPC: C12N7/00 ,  A61K39/145

Abstract: Provided is a method of producing reassortant influenza virus containing an antigenic protein of the first influenza virus strain, the method including the following steps: 1) a step of irradiating the first influenza virus strain with ultraviolet light in such an irradiation dose that the first influenza virus strain has initial infection ability and loses or is reduced in virus growth potential; 2) a step of infecting a host with the first influenza virus strain and the second influenza virus strain; 3) a step of culturing the host infected with the first influenza virus strain and the second influenza virus strain, to obtain culture product; 4) a step of inactivating influenza virus strain having an antigenic protein of the second influenza virus strain in the culture product obtained in the step 3); and 5) a step of collecting reassortant influenza virus after the step 4).

公开(公告)号：US20210130793A1

公开(公告)日：2021-05-06

申请号：US16639639

申请日：2018-08-23

Applicant: The Research Foundation for Microbial Diseases of Osaka University

Inventor： Takao Fujimoto

IPC: C12N7/00

Abstract: Provided is a production method for reassortant influenza virus having genome segments of two or more kinds of influenza virus in the case where an antigenic strain and donor strain have similar antigenicities. The production method makes use of the first influenza virus containing an antigenic protein, the second influenza virus having an antigenic protein having antigenicity similar to that of the strain, and the third influenza virus having an antigenic protein having antigenicity different from that of the strain, and includes the steps of: coculturing the strain and the strain by infecting a host therewith, to produce reassortant influenza viruses; selecting influenza virus having the antigenic protein from the viruses; then coculturing the strain and the selected strain by infecting a host therewith; and selecting influenza virus having the antigenic protein from reassortant influenza viruses produced from the strain and the strain.

公开(公告)号：US20210107789A1

公开(公告)日：2021-04-15

申请号：US17057007

申请日：2019-05-22

Applicant: The Research Foundation For Microbial Diseases of Osaka University

Inventor： Noriyuki Kanzawa ,  Shunsuke Kano ,  Hiroshi Miyatake

IPC: C01B25/36 ,  C07K1/14

Abstract: The present invention provides a substance which is useful as a carrier for protein purification. Since an aluminum phosphate compound that is obtained by a method for producing an aluminum phosphate compound, which comprises a step for obtaining a mixture that contains an aluminum phosphate compound by mixing an aqueous solution A containing a phosphate ion with an aqueous solution B containing an aluminum ion and a sulfate ion, and at least one of a potassium ion or a magnesium ion, exhibits excellent protein adsorption properties, this aluminum phosphate compound is useful as a carrier for protein purification.

公开(公告)号：US20150166639A1

公开(公告)日：2015-06-18

申请号：US14632555

申请日：2015-02-26

Applicant: The Research Foundation for Microbial Diseases of Osaka University

Inventor： Kimiyasu SHIRAKI ,  Yuka HAMA ,  Yoshihiro YOSHIDA ,  Masaaki TSUDA ,  Tadaharu TSUMOTO ,  Shunro ENDO ,  Michiaki TAKAHASHI

IPC: C07K16/08

CPC classification number: C07K16/088 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/74

Abstract: The invention provides agents that promote or inhibit neurite elongation comprising as an active ingredient an antibody that recognizes a varicella-zoster virus immediate-early protein and cross-reacts with a brain-derived neurotrophic factor. The invention also provides methods of utilizing such agents to prevent or treat a nervous disease or a disease with nerve hypersensitivity caused by a condition selected from the group consisting of postherpetic neuralgia, chronic pains, experience-dependent social aversion and stress.

Abstract translation: 本发明提供促进或抑制神经突伸长的药剂，其包含识别水痘带状疱疹病毒立即早期蛋白质并与脑源性神经营养因子交叉反应的抗体作为活性成分。 本发明还提供了利用这些药物来预防或治疗由选自带状疱疹后神经痛，慢性疼痛，经验依赖的社会厌恶和压力引起的神经过敏的神经疾病或疾病的方法。